Psoriasis of Scalp Clinical Trial
Official title:
Immune Spatial Features of Guselkumab Cutaneous Response
This study examines the effect of IL-23 blockade with Guselkumab on the immune cells of scalp psoriasis lesions.
Status | Recruiting |
Enrollment | 10 |
Est. completion date | June 30, 2026 |
Est. primary completion date | June 30, 2026 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: possess a PSSI (psoriasis scalp severity index) of =12 Exclusion Criteria: 1. taking systemic immunosuppressives in the last 4 weeks 2. pregnancy 3. severe immunodeficiency (either from genetic or infectious causes). 4. tuberculosis or other active serious infection 5. active systemic malignancy. 6. breast-feeding 7. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data. 8. Males who are trying to conceive - |
Country | Name | City | State |
---|---|---|---|
United States | University of California San Francisco | San Francisco | California |
Lead Sponsor | Collaborator |
---|---|
University of California, San Francisco | Janssen Scientific Affairs, LLC |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in psoriasis scalp severity index score (PSSI) | PSSI measures the extent of psoriasis involvement and the severity of erythema, infiltration, and desquamation of the scalp. PSSI scores will be taken pre- and mid-treatment. Scores range from 0 to 72, with higher scores indicating more severity. | baseline and 9 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00243464 -
Efficacy of Calcipotriol Plus Betamethasone Gel Versus Calcipotriol Scalp Solution in Scalp Psoriasis
|
Phase 3 | |
Recruiting |
NCT05144165 -
Systemic Treatment of Moderate-to-severe Psoriasis in Adults: Update of the French Guidelines
|
||
Completed |
NCT05105139 -
Study to Evaluate the Safety of Sebryl® and Sebryl Plus® in Seborrheic Dermatitis and Psoriasis of Scalp
|
||
Completed |
NCT00216827 -
Efficacy and Safety of Calcipotriol Plus Betamethasone Gel in the Treatment of Scalp Psoriasis
|
Phase 3 | |
Recruiting |
NCT04099979 -
A Pilot Study to Explore the Role of Gut Flora in Psoriasis
|
||
Not yet recruiting |
NCT03553433 -
Apremilast Treatment for Pruritus and Quality of Life in Scalp Psoriasis
|
Phase 4 | |
Recruiting |
NCT05938361 -
Efficacy of Tildrakizumab in Difficult-to-treat Areas in Psoriasis
|
||
Completed |
NCT00216879 -
Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel for up to a Year in Scalp Psoriasis
|
Phase 3 | |
Completed |
NCT00216840 -
Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel in Scalp Psoriasis
|
Phase 3 |